Table 4.

Adjusted associations between concentrations of reproductive hormones and mortality within 90-day in men and women hospitalized with COVID-19.

	Men			Women
	Odds ratio, adjusted* (95% CI)	P-value	Adjusted for IL-6	Odds ratio, adjusted* (95% CI)	P-value	Adjusted for IL-6
1st COVID-19 cohort
Testosterone (per two-fold reduction)	3.51 (1.77–6.94)	<0.001	2.00 (0.97–4.13)	0.87 (0.38–1.99)	0.744	1.01 (0.37–2.76)
Estrone sulfate (per two-fold reduction)	0.50 (0.32–0.77)	0.002	0.69 (0.41–1.18)	1.44 (0.86–2.42)	0.165	0.84 (0.48–1.48)
LH (per two-fold reduction)	1.97 (1.14–3.43)	0.016	1.38 (0.80–2.38)	1.25 (0.90–1.73)	0.180	1.30 (0.88–1.92)
FSH(per two-fold reduction)	1.54 (0.95–2.50)	0.081	0.82 (0.45–1.49)	1.49 (0.96–2.32)	0.073	1.57 (0.95–2.60)
2nd COVID-19 cohort
Testosterone (per two-fold reduction)	1.34 (0.70–2.57)	0.377	1.19 (0.60–2.35)	0.68 (0.20–2.37)	0.545	0.72 (0.12–4.42)
Estrone sulfate (per two-fold reduction)	1.04 (0.61–1.78)	0.884	1.48 (0.77–2.86)	1.85 (0.77–4.45)	0.167	0.35 (0.10–1.27)

^*Adjusted for age and presence or absence of comorbidity (hypertension, cancer, COPD, asthma, diabetes, or cardiovascular disease).

1st COVID-19 cohort, patients hospitalized with COVID-19 from March 16 to June 16, 2020; 2nd COVID-19 cohort, patients hospitalized with COVID-19 from July 25 2020 to February 3, 2021; FSH, follicle-stimulating hormone; IL-6, interleukin-6; LH, luteinizing hormone.